Quick Answer
OnKure Therapeutics, Inc. reported Net Income of -$59.52 million for fiscal year 2025.
OnKure Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$59.52M | -13.0% |
| 2024 | -$52.67M | -49.2% |
| 2023 | -$35.31M | +32.0% |
| 2022 | -$51.95M | -30.6% |
| 2021 | -$39.77M | -104.3% |
| 2020 | -$19.46M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.70M | -27.2% | +4.5% |
| June 30, 2025 | -$15.39M | -8.8% | +3.4% |
| March 31, 2025 | -$15.93M | -67.0% | +8.7% |
| December 31, 2024 | -$17.44M | — | -50.9% |
| September 30, 2024 | -$11.56M | +39.8% | +18.3% |
| June 30, 2024 | -$14.14M | +27.6% | -48.3% |
| March 31, 2024 | -$9.54M | +36.9% | +50.3% |
| September 30, 2023 | -$19.20M | -47.6% | +1.7% |
- OnKure Therapeutics, Inc. showed a decrease of -13.0% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, OnKure Therapeutics, Inc.’s net income has declined by 205.8% (from -$19.46 million to -$59.52 million).
- The most recent figure is from OnKure Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: